The excitement surrounding positive data from a small early-stage study evaluating Bayer AG subsidary BlueRock Therapeutics LP's bemdaneprocel for Parkinson's disease is merited, according to the German major's pharma R&D chief Christian Rommel, while stressing the need for patience in advancing the stem cell-derived therapy.
Bayer Heralds Potential Of BlueRock Parkinson's Stem Cell Therapy
Early-Stage Signs Show Promise
Bayer pharma research head Christian Rommel has told Scrip he was excited about the Phase I data on Parkinson's disease prospect bemdaneprocel, which is comprised of dopamine-producing neurons derived from pluripotent stem cells, but also advocated caution at this early stage.
More from Neurological
• By
The Texas-based firm is giving up on the investigational Alzheimer’s therapy after a second Phase III failure left it with nowhere to go in the disease.
• By
The FOCUS study met its primary and key secondary endpoints, but lack of statistical significance on the higher dose and a crowded market raised questions.
• By
A decision from the FDA is due by 28 September.
• By
A new “quasi-experimental” study using UK National Health Service data might confirm that GSK’s shingles vaccine helps cut dementia cases.
More from Therapy Areas
• By
After a long wait for patients, Vykat has become the first drug approved for Prader-Willi syndrome symptoms, opening the market up for Soleno and future challengers.
• By
With its exon 53-skipping candidate already showing promise in 24-week data, Wave now has 48-week data showing improvements in muscle health and functional outcomes.
• By
J&J is confident that its bispecific antibody/kinase inhibitor combo’s overall survival win over AstraZeneca’s single-agent pill will shift the standard of care.